The content of his proposed topics is expected to be covered by other speakers as agency staff plan to summarize the available data onthe cardiovascular safety of rosiglitazone at the committee meeting, and multiple FDA speakers will address their review of the readjudication of RECORDtrial based onthe study reports submitted to the Agency.